Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNorthwestern Mutual Wealth Management Co
Latest Disclosed Ownership8,856 shares
Latest Disclosed Value $ 3,954,558
Northwestern Mutual Wealth Management Co reports 6.70% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Northwestern Mutual Wealth Management Co filed a 13F-HR form disclosing ownership of 8,856 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $3,954,558 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 10, 2026 disclosing 8,300 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 6.70% during the quarter. The current value of the position is $3,957,126 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,856 556 6.70 3,955 5.10 0.0024
2026-02-10 2025-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 8,300 -7 -0.08 3,763 15.65 0.0024
2026-02-05 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,453 8,146 1,242 0.0008
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,307 -3,225 -27.97 3,253 -36.64 0.0022
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,532 -1,505 -11.54 5,134 -18.77 0.0037
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,037 490 3.91 6,321 25.10 0.0052
2025-02-11 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,547 150 1.21 5,053 -12.37 0.0043
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,397 -3,545 -22.24 5,766 -22.83 0.0051
2024-08-16 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,942 7,647 92.19 7,471 115.55 0.0074
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,295 -322 -3.74 3,467 -1.11 0.0036
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,617 510 6.29 3,506 24.38 0.0040
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,107 -781 -8.79 2,819 -9.88 0.0037
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,888 -774 -8.01 3,128 2.73 0.0040
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,662 122 1.28 3,044 10.53 0.0042
2023-02-21 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,540 416 4.56 2,755 4.24 0.0042
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,124 -23 -0.25 2,642 2.48 0.0046
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,147 -433 -4.52 2,578 3.08 0.0044
2022-05-09 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,580 2,024 26.79 2,501 50.66 0.0040
2022-02-03 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,556 1,995 35.87 1,660 64.68 0.0027
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,561 -662 -10.64 1,008 -19.68 0.0018
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,223 -4,001 -39.13 1,255 -42.88 0.0024
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,224 -3,385 -24.87 2,197 -31.71 0.0047
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,609 2,444 21.89 3,217 5.89 0.0074
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,165 8,223 279.50 3,038 255.32 0.0082
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,942 773 35.64 855 65.70 0.0026
2020-05-08 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,169 268 14.10 516 24.04 0.0020
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,901 -328 -14.72 416 10.05 0.0014
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,229 -55 -2.41 378 -9.79 0.0014
2019-08-12 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,284 122 5.64 419 5.28 0.0017
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,162 281 14.94 398 27.56 0.0017
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,881 -60 -3.09 312 -16.58 0.0016
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,941 125 6.88 374 21.04 0.0019
2018-08-10 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,816 338 22.87 309 28.22 0.0017
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,478 410 38.39 241 50.63 0.0015
2018-01-31 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,068 49 4.81 160 3.23 0.0010
2017-11-07 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,019 31 3.14 155 22.05 0.0011
2017-08-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 988 132 15.42 127 36.56 0.0010
2017-05-09 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 856 -547 -38.99 93 -9.71 0.0008
2017-02-15 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,403 22 1.59 103 -14.17 0.0011
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,381 30 2.22 120 3.45 0.0018
2016-08-29 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,351 -166 -10.94 116 -3.33 0.0017
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,517 357 30.78 120 -17.81 0.0019
2016-02-16 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,160 906 356.69 146 461.54 0.0029
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 254 -48 -15.89 26 -29.73 0.0006
2015-09-30 2015-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 302 53 21.29 37 27.59 0.0010
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 248 29
2015-05-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 249 34 15.81 29 11.54 0.0008
2015-02-13 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 215 15 7.50 26 18.18 0.0008
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 200 0 0.00 22 15.79 0.0008
2014-08-05 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 200 36 21.95 19 58.33 0.0007
2014-05-15 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 164 -471 -74.17 12 -74.47 0.0005
2014-02-14 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 635 587 1,222.92 47 1,075.00 0.0021
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 48 -223,489 -99.98 4 -99.98 0.0002
2013-08-14 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 223,537 223,537 17,854 0.1963
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.